TICs maintain lower intracellular ROS levels than other cancer cells within the tumor, primarily through the accumulation of ROS scavengers like glutathione and the overexpression of Gclm and glutathione synthetase, the enzymes necessary for its synthesis, as shown in breast and liver cancer stem cells [18, 20]. This evidence concerns the gene GCLM and neoplasm.